Ken Griffin Exagen Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exagen Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,500 shares of XGN stock, worth $24,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,500
Previous 2,500
80.0%
Holding current value
$24,839
Previous $4,000
225.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XGN
# of Institutions
38Shares Held
6.41MCall Options Held
4.5KPut Options Held
400-
Rtw Investments, LP New York, NY1.51MShares$8.35 Million0.07% of portfolio
-
Cowen And Company, LLC891KShares$4.92 Million0.07% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY541KShares$2.99 Million0.01% of portfolio
-
Stonepine Capital Management, LLC Bend, OR534KShares$2.95 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA491KShares$2.71 Million0.0% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $89.8M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...